Related Experiment Video
Updated: Feb 27, 2026
09:20
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
7.1K
Heart Failure with Preserved Ejection Fraction: Entresto a Possible Option
Taylor Bramblett1, Mohamed Teleb2, Aymen Albaghdadi3
1Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, Texas, United States.
Summary
Heart failure with preserved ejection fraction (HFpEF) affects many patients but lacks effective treatments. A new drug, LCZ696 (entresto), shows promise for managing HFpEF, offering new hope for patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure with preserved ejection fraction (HFpEF) accounts for 50% of heart failure cases.
- HFpEF shares similar outcomes with heart failure with reduced ejection fraction (HFrEF) but has treatment disparities.
- Diagnosis involves symptoms, preserved ejection fraction (>50%), and abnormal diastolic function.
Purpose of the Study:
- To review the limited efficacy of current HFpEF treatments.
- To explore the potential of LCZ696 (entresto) in managing HFpEF.
Main Methods:
- Review of studies on angiotensin receptor blockers (ARBs), thiazide diuretics, and ACE inhibitors for HFpEF.
- Discussion of the novel drug LCZ696 (entresto), a combination of angiotensin receptor neprilysin inhibitor and ARB.
Main Results:
- Previous treatments like ARBs, diuretics, and ACE inhibitors demonstrated only moderate efficacy without clear benefits for HFpEF.
- LCZ696 (entresto) has been approved by the FDA for potential HFrEF treatment, with ongoing interest in its HFpEF application.
Conclusions:
- Established treatment modalities have shown limited success in managing HFpEF.
- LCZ696 (entresto) represents a promising novel therapeutic option for patients with HFpEF.
Related Concept Videos
01:30Heart Failure V: Medical Management
419
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
419
01:30Heart Failure IV: Classification and Diagnostic Evaluation
476
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
476
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:22Heart Failure VI: Adjunct Therapies
466
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
466
01:26Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
508
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
508